Business
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing.
About this update from Oncology Pharma Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services of DBBMcKennon, LLC, a PCAOB Certified Public Accounting Firm. The Company has retained the firm to conduct an audit of its financials in order to become compliant with SEC reporting standards as it look towards its intended NASDAQ Capital Markets Listing. The management team has been diligently working towards positioning the Company into a setting where it can support the momentum, growth and movement of the Company as it looks towards the future.DBBMcKennon is a full-service, PCAOB Registered Certified Public Accounting firm, providing audit, tax, and consulting services to individuals and businesses through its offices located in Newport Beach, San Diego, and Santa Monica, CA.A spokesman from the Company stated "we are excited to be working with DBBMcKennon and the prospect of an uplisting." More to follow as material events become available.ABOUT ONCOLOGY PHARMA, INC.ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.FORWARD LOOKING STATEMENTSCertain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower...